Timothy Bubb, Technical Director, IMed Consultancy12.19.23
In the ever-evolving intersection of healthcare and technology, the regulatory landscape for medical devices is facing rapid transformation, leading to evolving regulatory compliance requirements for medical devices. Recent advancements in AI and robotics, paired with the continuous development and deployment of innovative devices, have created immense opportunities for enhancing patient care and reshaping the healthcare industry.
Simultaneously, regulators are adapting to ensure patient safety, device effectiveness, and ethical standards are upheld throughout the product lifecycle, making regulatory compliance for medical devices more intricate than ever before.
Only a deep understanding of the changing regulatory landscape, meticulous planning, robust quality management systems, and effective risk assessment strategies can help manufacturers truly get to grips with complex standards, guidelines and national regulations to ensure seamless market entry or expansion into new territories.
The stakes are high for businesses addressing these challenges, as the global medical devices market size reached $512.29 billion in 2022, projected to grow to $799.67 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 5.9% over the period.1 To navigate with confidence complex standards, guidelines and national regulations, ensuring seamless market entry or expansion into new territories, manufacturers need to understand the changing regulatory landscape, plan meticulously, have robust quality management systems and effective risk assessment strategies in place.
While the pathway for novel devices may be challenging, most medium-risk devices typically require a more straight-forward 510(k) registration, provided manufacturers can demonstrate safety and effectiveness compared to an equivalent legally marketed device. Gaining access to all the information about the predicate, when this has been manufactured by another company, may however prove difficult. Information will be restricted to that in the public and critical technical information will be hard to come by.
Despite the need to ensure the device QMS meets FDA requirements (21 CFR Part 820), overall regulatory approval fees are also generally lower than in the EU. Other key requirements are establishment registration and if the company is based outside of the USA, finding a US Agent (21 CFR Part 807).
The journey toward approval in the EU is complex and lengthy, with medium and higher risk products requiring a comprehensive technical file dossier and engagement with a Notified Body (NB) to certify the device, evaluate their QMS, review their technical documentation and assess their clinical evidence.
Recently, capacity concerns with NBs have caused delays, impacting time-to-market and patient access to vital devices. Despite challenges, the EU Commission is actively addressing issues to enhance the appeal of the EU market and safeguard patients from potential risks associated with a shortage of new, innovative, and existing medical devices, working to simplify the transition to the EU MDR/IVDR and extending deadlines for the implementation of new regulations, which eases the burden on products already certified under older regulations.
With a mature regulatory system, the UK is positioning itself as a hub for innovative products such as AI and software devices, especially with the recent release of The Medical Technology Strategy plan3, signalling that the UK is open to embrace innovation and opening up new, swifter routes to market for innovative medical devices.
On the other hand, the UK's shift to the new Medical Device Regulation (MDR) is underway, and the pace at which new requirements are emerging may catch many medical device manufacturers off guard. To accommodate the diverse requirements of advancing cutting-edge technologies, the UK is also exploring the recognition of approvals from other countries to expedite market access.
For medical device manufacturers, choosing an initial market entry strategy is complex, and understanding the nuances of regulatory systems in major markets is therefore crucial. However, embarking on this journey without the guidance of experienced professionals can pose unwarranted risks in today's dynamic regulatory environment. Enlisting the support of international regulatory specialists can make the difference when it comes to navigating market intricacies, managing regulatory expectations, and structuring a well-informed and strategic market entry approach.
With more than ten years’ experience in QA/RA roles, Tim Bubb has breadth and depth of knowledge across the regulatory, engineering, clinical, design and development, and quality assurance disciplines. Bubb has a passion for empowering innovation in medical devices, and brings insight and pragmatism to projects bringing complex lifesaving and life enhancing products to market.
References:
[1] Fortune Business Insights, The global medical devices market size was valued at $512.29 billion in 2022 & is projected to grow from $536.12 billion in 2023 to $799.67 billion by 2030, https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085
2 MedTech Europe, The European Medical Technology in Figures, Market (Last update 19.09.2022) https://www.medtecheurope.org/datahub/market/
3 Medical Technology Strategy Plan, February 2023, https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy
Simultaneously, regulators are adapting to ensure patient safety, device effectiveness, and ethical standards are upheld throughout the product lifecycle, making regulatory compliance for medical devices more intricate than ever before.
Only a deep understanding of the changing regulatory landscape, meticulous planning, robust quality management systems, and effective risk assessment strategies can help manufacturers truly get to grips with complex standards, guidelines and national regulations to ensure seamless market entry or expansion into new territories.
The stakes are high for businesses addressing these challenges, as the global medical devices market size reached $512.29 billion in 2022, projected to grow to $799.67 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 5.9% over the period.1 To navigate with confidence complex standards, guidelines and national regulations, ensuring seamless market entry or expansion into new territories, manufacturers need to understand the changing regulatory landscape, plan meticulously, have robust quality management systems and effective risk assessment strategies in place.
Placing a device on the U.S. Market
The U.S., boasting a medical device market valued at USD 176.7 billion in 2020, according to Grandview Research, offers an intriguing entry point despite the FDA's reputation for strict regulation.While the pathway for novel devices may be challenging, most medium-risk devices typically require a more straight-forward 510(k) registration, provided manufacturers can demonstrate safety and effectiveness compared to an equivalent legally marketed device. Gaining access to all the information about the predicate, when this has been manufactured by another company, may however prove difficult. Information will be restricted to that in the public and critical technical information will be hard to come by.
Despite the need to ensure the device QMS meets FDA requirements (21 CFR Part 820), overall regulatory approval fees are also generally lower than in the EU. Other key requirements are establishment registration and if the company is based outside of the USA, finding a US Agent (21 CFR Part 807).
The EU Medical Device Market – a Brief Introduction
With a 24.5%2 share of global medical device sales, the European Union follows closely behind the U.S., with in vitro diagnostics (IVD) representing the largest sub-sector of devices.The journey toward approval in the EU is complex and lengthy, with medium and higher risk products requiring a comprehensive technical file dossier and engagement with a Notified Body (NB) to certify the device, evaluate their QMS, review their technical documentation and assess their clinical evidence.
Recently, capacity concerns with NBs have caused delays, impacting time-to-market and patient access to vital devices. Despite challenges, the EU Commission is actively addressing issues to enhance the appeal of the EU market and safeguard patients from potential risks associated with a shortage of new, innovative, and existing medical devices, working to simplify the transition to the EU MDR/IVDR and extending deadlines for the implementation of new regulations, which eases the burden on products already certified under older regulations.
Entering the UK Medical Device Market
While smaller in comparison to the U.S. and EU ones, the UK's medical device market holds global significance. The absence of language barriers and the appeal of the "one provider/one payer" model which can be used with the National Health Service (NHS) integrated supply chain, make it an attractive market.With a mature regulatory system, the UK is positioning itself as a hub for innovative products such as AI and software devices, especially with the recent release of The Medical Technology Strategy plan3, signalling that the UK is open to embrace innovation and opening up new, swifter routes to market for innovative medical devices.
On the other hand, the UK's shift to the new Medical Device Regulation (MDR) is underway, and the pace at which new requirements are emerging may catch many medical device manufacturers off guard. To accommodate the diverse requirements of advancing cutting-edge technologies, the UK is also exploring the recognition of approvals from other countries to expedite market access.
For medical device manufacturers, choosing an initial market entry strategy is complex, and understanding the nuances of regulatory systems in major markets is therefore crucial. However, embarking on this journey without the guidance of experienced professionals can pose unwarranted risks in today's dynamic regulatory environment. Enlisting the support of international regulatory specialists can make the difference when it comes to navigating market intricacies, managing regulatory expectations, and structuring a well-informed and strategic market entry approach.
With more than ten years’ experience in QA/RA roles, Tim Bubb has breadth and depth of knowledge across the regulatory, engineering, clinical, design and development, and quality assurance disciplines. Bubb has a passion for empowering innovation in medical devices, and brings insight and pragmatism to projects bringing complex lifesaving and life enhancing products to market.
References:
[1] Fortune Business Insights, The global medical devices market size was valued at $512.29 billion in 2022 & is projected to grow from $536.12 billion in 2023 to $799.67 billion by 2030, https://www.fortunebusinessinsights.com/industry-reports/medical-devices-market-100085
2 MedTech Europe, The European Medical Technology in Figures, Market (Last update 19.09.2022) https://www.medtecheurope.org/datahub/market/
3 Medical Technology Strategy Plan, February 2023, https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy